Recognized for its representation of business development companies (BDCs), Dechert's capital markets practice excels in global offerings for issuers and underwriters. In Boston, co-leader Thomas Friedmann advises US and non-US issuers, investment banks, and alternative asset managers on public and private securities offerings, including BDCs and closed-end funds. In Philadelphia, co-leader Stephen Leitzell represents public and private companies, private equity sponsors, and portfolio companies across industries, focusing on healthcare and technology. In Washington DC, co-leader Harry Pangas handles BDCs, closed-end funds, interval funds, and tender offer funds in their formation, structuring, and distribution. In Philadelphia, Eric S Siegel advises issuers and investment banks on equity and debt securities offerings, and Ian A Hartman is a notable contact.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Lawyer & team quality
Client satisfaction: Sector knowledge
Key clients
- Aquestive Therapeutics
- B&G Foods
- Bain Capital Specialty Finance
- BC Partners
- BioAtla
- Blackstone
- Business Development Company of America
- Diffusion Therapeutics
- EaglePoint Credit Company
- FS Investment Corporation
- Golub Capital BDC, Inc.
- Griffon Corporation
Work highlights
Represented Crown Holdings in connection with multiple debt offerings, including its offering of US$700 million aggregate principal amount of 5.875% senior unsecured notes due 2033 issued at par by its subsidiary Crown Americas LLC and its offering of €500 million aggregate principal amount of 3.750% senior unsecured notes due 2031 issued at par by its subsidiary Crown European Holdings S.A.
Advised French biotech company Abivax SA (Euronext Paris: FR0012333284 – ABVX) in connection with its approximately US$747.5 million public offering (equivalent to €637.5 million), consisting of American Depositary Shares (ADSs) listed on the Nasdaq Global Market. This marks a record-breaking transaction for a French biotech.
Represented Barings LLC as selling stockholder in connection with Accelerant Holding's US$723 million initial public offering. In addition to the approximately 20.2 million shares offered by Accelerant, Barings and other existing shareholders sold approximately 14.2 million shares at $21 dollars a piece.
Practice head
Thomas Friedmann; Stephen Leitzell; Harry Pangas
Other key lawyers
Eric S Siegel; Ian A Hartman